Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 240 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intestinal Malabsorption Clear all
Recruiting Not applicable Interventional

Gluten Technology and Education for Celiac Health

NCT06059716
View directory record Official record
Conditions
Celiac Disease
Interventions
Gluten detection technology, Continuous telemedicine monitoring
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 18, 2026, 3:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gut Permeability Assessment in Celiac and Gluten Sensitive Children

NCT02690532
View directory record Official record
Conditions
Celiac Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 18, 2026, 3:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 2 Interventional

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

NCT01396213
View directory record Official record
Conditions
Celiac Disease
Interventions
Larazotide Acetate, placebo
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
56
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Not applicable Interventional

Comparison of Different Oral Rehydration Solutions

NCT02142582
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
WHO ORS, Commercial ORS
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 18, 2026, 3:27 AM EDT
Terminated Not applicable Interventional

Effect of a Short Message Service Intervention on Patients With Short Bowel Syndrome

NCT03419156
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Text Message Arm Intervention
Other
Lead sponsor
St. Louis University
Other
Eligibility
Up to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 18, 2026, 3:27 AM EDT
Withdrawn Not applicable Interventional

Fiber Use in Pediatric Short Bowel Syndrome

NCT00922805
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
guar gum
Dietary Supplement
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
2 Weeks to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 18, 2026, 3:27 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Combined Antibody Screening for Celiac and Diabetes Evaluation

NCT04677699
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Combined Risk Score
Diagnostic Test
Lead sponsor
Pacific Northwest Research Institute
Other
Eligibility
1 Day to 7 Years
Enrollment
64,410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 18, 2026, 3:27 AM EDT
Recruiting No phase listed Observational

Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

NCT07335523
View directory record Official record
Conditions
Exocrine Pancreatic Insuficiency
Interventions
Fecal Fat
Diagnostic Test
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
7 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Aurora, Colorado • New York, New York • Cincinnati, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Not applicable Interventional Results available

Microbial Basis of Systemic Malodor and "People Allergic To Me" Conditions

NCT03582826
View directory record Official record
Conditions
Nutritional and Metabolic Diseases
Interventions
Nutritional counselling, Stress-reduction counseling
Behavioral
Lead sponsor
Mebo Research, Inc.
Other
Eligibility
18 Years to 110 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

NCT00081458
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Placebo, Teduglutide 0.05 mg/kg/d, Teduglutide 0.1 mg/kg/d
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
14
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 18, 2026, 3:27 AM EDT
Completed No phase listed Observational

Intracellular Tight Junction Permeability in Schizophrenia: Focus on Zonulin

NCT01558570
View directory record Official record
Conditions
Schizophrenia, Celiac Disease
Interventions
Blood Draw
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 18, 2026, 3:27 AM EDT
Terminated Phase 2 Interventional

Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients

NCT04243551
View directory record Official record
Conditions
Celiac Disease
Interventions
Latiglutenase, Placebo
Drug · Other
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 18, 2026, 3:27 AM EDT
Not listed No phase listed Observational

A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients

NCT01594541
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
55 Years to 89 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

NCT00798967
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
La Jolla, California • Washington D.C., District of Columbia • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 18, 2026, 3:27 AM EDT
No Longer Available No phase listed Expanded access

Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis

NCT02148146
View directory record Official record
Conditions
Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)

NCT02954458
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
TED, SOC, Syringe, Needle
Drug · Other · Device
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 18, 2026, 3:27 AM EDT
Terminated Phase 2 Interventional

Study of Latiglutenase in T1D/CD Patients

NCT04839575
View directory record Official record
Conditions
Celiac Disease
Interventions
Latiglutenase, Placebo
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 18, 2026, 3:27 AM EDT
Terminated Phase 4 Interventional Results available

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

NCT02476994
View directory record Official record
Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
Clinolipid, Intralipid
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Up to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Park Ridge, Illinois • Indianapolis, Indiana • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 18, 2026, 3:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Fiber Food Introduction in Pediatric Short Bowel Syndrome

NCT05432648
View directory record Official record
Conditions
Short Gut Syndrome
Interventions
Green bean puree
Dietary Supplement
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Months to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies

NCT01674478
View directory record Official record
Conditions
Prematurity, Intestine Perforation, Necrotizing Enterocolitis (NEC), Short Bowel Syndrome (SBS)
Interventions
Microlipid with fish oil, Microlipid
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
1 Day to 2 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

NCT03690206
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
glepaglutide, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 18, 2026, 3:27 AM EDT
Not listed Not applicable Interventional

Pectin Use in Pediatric Intestinal Rehabilitation

NCT04224168
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Green Beans, Liquid Pectin
Dietary Supplement
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
6 Months to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 18, 2026, 3:27 AM EDT
Terminated Not applicable Interventional Results available

Innovative Central Line Securement Device in the Pediatric Population

NCT04522778
View directory record Official record
Conditions
Central Line Complication, Central Line Infection, Central Line-Associated Infection, Central Line Sepsis, Short Gut Syndrome, Quality of Life, Pediatric Disorder
Interventions
Wearable Central Line Securement Device (Vest), Traditional Securement Dressing
Device · Other
Lead sponsor
Ryan St. Pierre-Hetz
Other
Eligibility
0 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 18, 2026, 3:27 AM EDT